NG101 AAV Gene Therapy in Subjects with Wet Age-Related Macular Degeneration

Recruiting

Phase 1

Phase 2

NG101NG101 AAV Gene Therapy in Subjects with Wet Age-Related Macular Degeneration

Sponsor:

Neuracle Genetics, Inc

Code:

NCT05984927

Conditions

Age-Related Macular Degeneration

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Not accepted

Interventions

NG101 AAV gene therapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-27. This information was provided to ClinicalTrials.gov by Neuracle Genetics, Inc on 2025-03-27.